This is a summary of the European public assessment report (EPAR) for Nexium Control. It explains how the European Medicines Agency assessed the medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Nexium Control.
For practical information about using Nexium Control, patients should read the package leaflet or contact their doctor or pharmacist.
Nexium Control : EPAR - Summary for the public (PDF/74.66 KB)Adopted
First published: 19/09/2013
Last updated: 19/09/2013
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Pfizer Healthcare Ireland
|Date of issue of marketing authorisation valid throughout the European Union||
10/06/2020 Nexium Control - EMEA/H/C/002618 - IB/0029/G
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Nexium Control is indicated for the short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults.